Bristol Myers Squibb Company $BMY is Independent Franchise Partners LLP’s 2nd Largest Position

Independent Franchise Partners LLP trimmed its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 1.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 20,623,351 shares of the biopharmaceutical company’s stock after selling 353,603 shares during the quarter. Bristol Myers Squibb makes up approximately 6.1% of Independent Franchise Partners LLP’s investment portfolio, making the stock its 2nd largest position. Independent Franchise Partners LLP owned approximately 1.01% of Bristol Myers Squibb worth $930,113,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Darwin Wealth Management LLC acquired a new position in shares of Bristol Myers Squibb during the 2nd quarter worth about $25,000. Harbor Capital Advisors Inc. boosted its holdings in Bristol Myers Squibb by 107.2% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 313 shares during the last quarter. Total Investment Management Inc. acquired a new stake in Bristol Myers Squibb in the 2nd quarter worth about $38,000. Twin Peaks Wealth Advisors LLC purchased a new stake in Bristol Myers Squibb during the 2nd quarter worth approximately $40,000. Finally, Bank of Jackson Hole Trust raised its holdings in shares of Bristol Myers Squibb by 352.2% during the third quarter. Bank of Jackson Hole Trust now owns 1,040 shares of the biopharmaceutical company’s stock valued at $47,000 after acquiring an additional 810 shares during the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Price Performance

NYSE:BMY opened at $59.02 on Friday. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $62.89. The stock has a market cap of $120.18 billion, a PE ratio of 17.11, a P/E/G ratio of 0.17 and a beta of 0.26. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.14 and a current ratio of 1.26. The stock has a 50 day moving average price of $58.24 and a 200 day moving average price of $51.40.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). The company had revenue of $12.50 billion for the quarter, compared to analyst estimates of $12.24 billion. Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The business’s quarterly revenue was up 1.3% on a year-over-year basis. During the same period last year, the firm posted $1.67 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Equities research analysts expect that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, April 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.3%. Bristol Myers Squibb’s payout ratio is presently 73.04%.

Analyst Ratings Changes

Several equities analysts have recently weighed in on BMY shares. BMO Capital Markets restated a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday, November 17th. Guggenheim reissued a “buy” rating and issued a $72.00 price objective (up from $62.00) on shares of Bristol Myers Squibb in a research note on Friday, February 6th. Wells Fargo & Company restated an “outperform” rating and issued a $60.00 price objective (up from $55.00) on shares of Bristol Myers Squibb in a report on Friday, February 6th. Scotiabank reaffirmed a “sector perform” rating and set a $60.00 target price (up from $53.00) on shares of Bristol Myers Squibb in a research note on Friday, January 9th. Finally, UBS Group reaffirmed a “buy” rating and set a $70.00 target price on shares of Bristol Myers Squibb in a report on Friday, March 6th. Nine equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Bristol Myers Squibb currently has a consensus rating of “Hold” and an average target price of $61.00.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.